These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39214092)

  • 1. PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer.
    Somasundaram A; Sanoff HK
    Cancer Cell; 2024 Sep; 42(9):1489-1491. PubMed ID: 39214092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.
    Xiao WW; Chen G; Gao YH; Lin JZ; Wu XJ; Luo HL; Lu ZH; Wang QX; Sun R; Cai PQ; Zhu CM; Liu M; Li JB; Wang YR; Jin Y; Wang F; Luo HT; Li CL; Pan ZZ; Xu RH
    Cancer Cell; 2024 Sep; 42(9):1570-1581.e4. PubMed ID: 39094560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.
    Wang Y; Zhao L; Zhang Z; Liu P
    Oncoimmunology; 2024; 13(1):2416558. PubMed ID: 39429516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
    Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
    Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A; Lumish M; Sinopoli J; Weiss J; Shia J; Lamendola-Essel M; El Dika IH; Segal N; Shcherba M; Sugarman R; Stadler Z; Yaeger R; Smith JJ; Rousseau B; Argiles G; Patel M; Desai A; Saltz LB; Widmar M; Iyer K; Zhang J; Gianino N; Crane C; Romesser PB; Pappou EP; Paty P; Garcia-Aguilar J; Gonen M; Gollub M; Weiser MR; Schalper KA; Diaz LA
    N Engl J Med; 2022 Jun; 386(25):2363-2376. PubMed ID: 35660797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Node-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSS of Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial.
    Cai C; Zhang X; Sun X; Wang H; Chen E; Chen L; Gu B; Wang J; Huang X; Lao W; Wang X; Chen M; Ding S; Du J; Song Z
    BMC Cancer; 2024 Oct; 24(1):1247. PubMed ID: 39385104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
    Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
    BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.
    Fan Y; Zhu X; Xu C; Ding C; Hu J; Hong Q; Wang J
    BMJ Open; 2023 Mar; 13(3):e069401. PubMed ID: 36914193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    Li Y; Wang J; Ma X; Tan L; Yan Y; Xue C; Hui B; Liu R; Ma H; Ren J
    Int J Biol Sci; 2016; 12(8):1022-31. PubMed ID: 27489505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
    Noticewala SS; Das P
    Cancer J; 2024 Jul-Aug 01; 30(4):227-231. PubMed ID: 39042772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.
    Li Y; Pan C; Gao Y; Zhang L; Ji D; Cui X; Zhang X; Cai Y; Zhang Y; Yao Y; Wang L; Leng J; Zhan T; Wu D; Gao Z; Sun YS; Li Z; Luo H; Wu A
    JAMA Surg; 2024 May; 159(5):529-537. PubMed ID: 38381429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic effect of neoadjuvant chemoradiotherapy on the change of PD-L1 expression in patients with locally advanced rectal adenocarcinoma.
    Richter I; Jirasek T; Dvorak J; Cermakova E; Rehakova P; Bartos J
    J BUON; 2017; 22(4):875-881. PubMed ID: 29155514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer.
    Sun Z; Adam MA; Kim J; Turner MC; Fisher DA; Choudhury KR; Czito BG; Migaly J; Mantyh CR
    Colorectal Dis; 2017 Dec; 19(12):1058-1066. PubMed ID: 28586509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair-deficient, locally advanced rectal cancer.
    Mi M; Ye C; Yuan Y
    Signal Transduct Target Ther; 2022 Oct; 7(1):361. PubMed ID: 36216819
    [No Abstract]   [Full Text] [Related]  

  • 17. Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.
    Xiao W; Luo H; Yao Y; Wang Y; Liu S; Sun R; Chen G
    Front Immunol; 2023; 14():1149122. PubMed ID: 37033988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer.
    Bhudia J; Glynne-Jones R
    Curr Treat Options Oncol; 2022 Apr; 23(4):453-473. PubMed ID: 35312962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A prediction model of pathological complete response in patients with locally advanced rectal cancer after PD-1 antibody combined with total neoadjuvant chemoradiotherapy based on MRI radiomics].
    Zhang XY; Zhu HT; Li XT; Li YJ; Li ZW; Wang WH; Wu AW; Sun YS; Zhang L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):228-234. PubMed ID: 35340172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.